QOL OUTCOMES DURING LONG-TERM TREATMENT WITH DARIFENACIN FOR OVERACTIVE BLADDER (OAB): A 2-YEAR, OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Young, Jay [1 ]
Lheritier, Karine [2 ]
Steel, Michael [3 ]
Dwyer, Peter [4 ]
机构：
[1] Orange Cty Urol Associates, Med Res Ctr, Laguna Woods, CA USA
[2] Novartis Pharma AG, Biostat, Basel, Switzerland
[3] Novartis Pharma AG, Clin Dev & Med Affairs, Basel, Switzerland
[4] Mercy Hosp Women, Urogynaecol, Melbourne, Vic, Australia
来源：
QUALITY OF LIFE RESEARCH | 2005年 / 14卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
P-36/1678
引用
收藏
页码：2036 / 2036
页数：1
相关论文
共 50 条
  • [41] LONG-TERM PERAMPANEL USE IN OPEN-LABEL EXTENSION STUDIES
    Rektor, Ivan
    Krauss, Gregory L.
    Inoue, Yushi
    Kaneko, Sunao
    Williams, Betsy
    Patten, Anna
    Bibbiani, Francesco
    Laurenza, Antonio
    Wechsler, Robert T.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A23 - A23
  • [42] Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)
    Mohee, Amar
    Khan, Ayisha
    Harris, Neil
    Eardley, Ian
    BJU INTERNATIONAL, 2013, 111 (01) : 106 - 113
  • [43] LONG-TERM EFFICACY AND SAFETY PROFILE OF EZETIMIBE10MG IN TREATMENT OF PATIENTS WITH HOMOZYGOUS SITOSTEROLEMIA: A MULTI-CENTER, OPEN-LABEL, 2-YEAR EXTENSION STUDY
    Luetjohann, D.
    von Bergmann, K.
    Sirah, W.
    Shah, A.
    Lin, J.
    Sapre, A.
    Johnson-Levonas, A.
    Musliner, T.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 189 - 189
  • [44] Long-term efficacy and safety profile of ezetimibe 10 mg in the treatment of patients with homozygous sitosterolemia: A multi-center, open-label, 2-year extension
    Musliner, Thomas
    Sirah, Waheeda
    Shah, Arvind
    Lin, Jianxin
    Sapre, Aditi
    Levonas, Amy Johnson
    Luetjohann, Dieter
    vonBergmann, Klaus
    CIRCULATION, 2007, 116 (16) : 93 - 93
  • [45] Long-term lumateperone treatment in bipolar disorder: Six-month open-label extension study
    Tohen, Mauricio
    D'Souza, Ian
    Kozauer, Susan G.
    Chen, Changzheng
    Durgam, Suresh
    BIPOLAR DISORDERS, 2023, 25 : 96 - 96
  • [46] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study
    Ashina, M.
    Roos, C.
    Ayer, D. W.
    Ruff, D.
    Krege, J. H.
    Li, L. Q.
    Komori, M.
    HEADACHE, 2022, 62 : 113 - 114
  • [47] Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-Label Extension Study
    Tohen, Mauricio
    Durgam, Suresh
    Kozauer, Susan
    D'Souza, Ian
    Chen, Richard
    Mates, Sharon
    CNS SPECTRUMS, 2023, 28 (02) : 233 - 233
  • [48] Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
    Ashina, M.
    Roos, C.
    Ayer, D.
    Ruff, D.
    Krege, J.
    Li, L. Q.
    Komori, M.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [49] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    GUT, 2018, 67 : A62 - A63
  • [50] Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
    Devinsky, Orrin
    Nabbout, Rima
    Miller, Ian
    Laux, Linda
    Zolnowska, Marta
    Wright, Stephen
    Roberts, Claire
    EPILEPSIA, 2019, 60 (02) : 294 - 302
12345